Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea wins Canadian approval for new antibiotic
Basilea Pharmaceuticals will co-promote the drug in Canada under the trade name Zeftera with its local partner Janssen-Ortho. Ceftobiprole is currently under review by regulatory authorities in the
Basilea Pharmaceuticals will co-promote the drug in Canada under the trade name Zeftera with its local partner Janssen-Ortho. Ceftobiprole is currently under review by regulatory authorities in the
The study did not achieve statistical significance on either of its primary endpoints – cognition and activities of daily living. Peter Meldrum, president and CEO of Myriad Genetics,
Enbrel 25mg Syringe 0.5mL for SC Injection is a new formulation of the existing Enbrel 25mg for SC Injection, with the drug pre-filled into the syringe. According to
Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also
Dronabinol is the generic version of Solvay Pharmaceuticals’s Marinol CIII capsules, indicated to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond
Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor’s proprietary compound library, and plate and replicate these compounds for a
Golimumab, Centocor’s next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also being studied as an intravenous (IV) infusion therapy.
The companies also terminated the Schering-Plough and Merck Pharmaceuticals respiratory joint venture, which was formed in May 2000 to develop and market a fixed-combination product that would combine
The FDA approval was based on clinical trial data in adults ages 18 to 65. In these studies, use of Concerta was shown to significantly improve ADHD symptoms
The purchase price for Clinical Laboratories of Hawaii (CLH) of $121 million equates to a prospective EBITDA (post synergies) multiple of approximately 6.2 times, after allowing for the